BioSante Completes Cell Genesys Buyout
BioSante-Cell Genesys to focus on developing therapy to treat female sexual dysfunction
03:13PM 10/14/09
BioSante Alters Terms Of Cell Genesys Deal
BioSante adjusts exchange ratio in Cell Genesys acquisition; cos. to vote on tie-up Sept. 30
12:00PM 09/23/09
Mad About Options: Dendreon Flashback
The Mad About Options crew takes a look back Dendreon.
01:30PM 07/14/09
Options Recap: Bulls Grab SL Green
Bullish traders bought SL Green Realty and Cell Genesys options, OptionMonster says.
08:48AM 05/12/09
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
09:48AM 05/06/09
Mad About Options: Poor Dendreon
The Mad About Options crew reviews Cramer's bearish take on Dendreon and offers options strategies for traders and investors.
09:41AM 05/06/09
Four Must-See Charts: Biotech Stocks
These speculative biotech stocks could be setting up to make significant moves in the near future.
03:24PM 04/30/09
Heartland Payment Chairman Sells Stock
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
10:02AM 04/22/09
JPMorgan Insider Sells $1.2M Worth
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
09:30AM 04/20/09
Shutterfly Insider Sells $580,000 Worth
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
09:28AM 04/09/09
CEO Robert Toll Sells $3.6M of Toll Brothers
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
09:53AM 04/03/09
Biotech Stock Mailbag: Fans Rally 'Round Arena
Arena fans take issue with a column outlining the company's challenges.
07:59AM 03/27/09
Cell Genesys' Net Loss Reduces
A payment from Takeda Pharmaceutical related to the termination of a collaborative agreement between the two companies contributed to increased revenue in the fourth quarter of fiscal 2008.
01:11PM 03/10/09
Don't Be Tempted by Penny-Stock Portfolio
While $1 stocks might appear to be a cheap investment, an increased amount in delistings and bankruptcies should be a source of concern.
09:14AM 02/11/09
Biotech Scorecard: My Best and Worst Calls
Biotech expert Adam Feuerstein grades his hits and misses for 2008.
06:59AM 01/02/09



Connect with TheStreet